Ronald Lieberman - Concepedia

Author

Ronald Lieberman

National Cancer Institute

Also Known As

R H Lieberman, R Lieberman, R. Lieberman, RONALD LIEBERMAN, Ronald Lieberman

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health The University of Texas MD Anderson Cancer Center University of Pittsburgh University of California, San Francisco

About

Ronald Lieberman is an author at National Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	650
2	Health Sciences	2	2	51
3	Business	1	1	42
4	Engineering	1	1	15
5	Public Health	1	1	12

Ronald Lieberman

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Chris H. Takimoto, Kira Glover-Cutter, Xiaoke Huang, PubMed Unconjugated Soy IsoflavonesTotal GenisteinFree GenisteinIsoflavone GenisteinFood Bioactive Compound	2003	129
ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER Philip M. Arlen, James L. Gulley, N. Todd, The Journal of Urology	2005	109
The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial Anne R. Simoneau, Eugene W. Gerner, Ray B. Nagle, Cancer Epidemiology Biomarkers & Prevention	2008	95
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. William L. Dahut, Nancy Harold, Chris H. Takimoto, Journal of Clinical Oncology	1996	71
Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer Gary J. Kelloff, Ronald Lieberman, Vernon E. Steele, Urology UrologyChemopreventive Agent DevelopmentChemoprevention StrategyMedicinePharmacology	2001	66
Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine Stephen C. Piscitelli, Alain Thibault, William D. Figg, The Journal of Clinical Pharmacology	1995	62
Pharmacokinetics of amifostine: effects of dose and method of administration. Heather S. Bonner, Lynn M. Schuchter, Joan H. Schiller, PubMed	1999	57
Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia James R. Marshall, Wael Sakr, David P. Wood, Cancer Epidemiology Biomarkers & Prevention	2006	50
Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells Yu‐Jui Yvonne Wan, Bonnie M. Orrison, Ronald Lieberman, Journal of Cellular Physiology	1987	43
Adaptive control with feedback strategies for suramin dosing Michael R. Cooper, Ronald Lieberman, Renato V. La Rocca, Clinical Pharmacology & Therapeutics Therapeutic Drug MonitoringControl MethodFeedback StrategiesPharmacodynamicsMedicine	1992	42

Page 1